Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PARSOL 1789 GRAS/E STATUS NOT IMPEDED BY SHADE OVAGUARD NDA, GIVAUDAN-ROURE

This article was originally published in The Tan Sheet

Executive Summary

PARSOL 1789 GRAS/E STATUS NOT IMPEDED BY SHADE OVAGUARD NDA, GIVAUDAN-ROURE counsel Edward Basile of the Washington, D.C. law firm King & Spalding asserted in an April 26 letter to FDA. Addressing comments made by Shade UVAGuard marketer Schering- Plough to FDA on March 17 ("The Tan Sheet" April 11, p. 10), Basile said Givaudan-Roure was "surprised" that Schering would suggest "that the avobenzone we supply to Schering-Plough under the tradename Parsol 1789 has not been sufficiently reviewed by the agency to establish its status as a generally recognized as safe and effective ingredient."

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel